Introduction
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), affects about 2.5 to 3.0 million Europeans and 1.6 million Americans. [1] [2] Recent epidemiological studies reported that the incidence and prevalence of IBD are increasing worldwide, making IBD a global disease. [3] The overall health care cost for IBD and necrotizing enterocolitis is estimated to be about $23 billion dollars per year, which includes the combined price of medicine and surgery, hospitalization, and loss of productivity. [1] [2] [3] [4] [5] CD is an immunologically mediated, chronic remittent, and relapsing inflammatory disease that affects the entire gastrointestinal tract. It is characterized by transmural inflammation with resultant formation of fibrotic stricture and final intestinal fibrosis, which is due to overgrowth of the muscularis layers. This overgrowth is characterized by smooth muscle cell hyperplasia and hypertrophy and excessive deposition of extracellular matrix. [6] [7] [8] [9] [10] Chronic inflammation (lifelong)-induced muscularis thickening and fibrosis in CD occurs in the muscularis mucosa and muscularis propria. In this case, a distinctive inflammatory pattern emerges in the intestine, which is subjected to a variety of stimuli, including gut microbiota, genetic mutation, environmental exposure, and chemical contact, and it is mediated by a series of complicated immunological responses and a collaboration of different immune cells. [6] [7] [8] [9] [10] Although the mechanism of fibrosis and related issues in CD have been investigated for several decades, a comprehensive understanding of the pathophysiological mechanisms of intestinal fibrosis remains to be identified and, hence, the exploration of novel therapeutic approaches. [6] [7] [8] [9] [10] Here, I summarize the current knowledge on the primary mechanisms of intestinal fibrosis, with a specific emphasis on the role of microRNAs, propose new research pathways and questions, and suggest the potential needs for the study of fibrosis in IBD.
by the deposition of ECM. [11] [12] Once the fibrotic process is terminated, tissue remodeling occurs through maintenance of a balance between ECM production and its degradation. [11] [12] [13] [14] [15] During chronic inflammation, the epithelial and endothelial barriers are disrupted, resulting in activation of intestinal mesenchymal cells, such as smooth muscle cells, fibroblasts, and subepithelial myofibroblasts (SEMFs), by a variety of cytokines, mediators, bacterial products, and growth factors. [16] [17] [18] [19] Potential crosstalk between intestinal epithelial cells and SEMFs occurs, as stimulation of epithelial cells inhibits mobility/migration of SEMFs, which potentially contributes to the retention of SEMFs at inflammatory foci in vivo and increased collagen production in SEMFs. [20] Moreover, loss of the negative feedback regulation leads to fibrosis with sustained activation of SEMFs and excess transforming growth factor (TGF)-β1 and collagen production and cellular proliferation. [20] Once SEMFs are activated in patients susceptible to fibrostenosis, autocrine mechanisms lead to fibrosis, production of TGF-β1 and collagen I, and cellular proliferation, which continues even in the absence of sustained inflammation. [10, [16] [17] [18] [19] [20] Intestinal fibrosis that is associated with CD is a dynamic tissue remodeling process that is characterized by pathological tissue repair or wound healing process, which depend on the balance between production of ECM components and activity of proteolytic enzymes, such as matrix metalloproteinases (MMPs) and tissue inhibitor of MMPs (TIMPs). [11] [12] [13] [14] [15] More specifically, reduced MMP activity and/or upregulated TIMP protein levels appear to contribute to dense collagen deposition during stricture formation. Intestinal fibrosis in CD-associated strictures requires activated ECM-secreting myofibroblasts to perpetuate the fibrotic response and to sustain tissue remodeling and stricture formation. [16] [17] [18] [19] Crosstalk between colonic epithelial cells and subepithelial myofibroblasts may recruit other cell types to differentiate into active myofibroblasts through several molecular mechanisms, including epithelial-to-mesenchymal transition (EMT) and endothelial-mesenchymal transition (EndoMT), defective apoptosis, enhanced proliferation of myofibroblasts, mesenchymal cells migration into inflamed region, and intestinal stem cells differentiation. [16] [17] [18] [19] In Table 1 , I summarize protein markers used to identify major components of mesenchymal cells that contribute to intestinal fibrosis. [21] [22] [23] [24] [25] TGF-β signaling TGF-β and its downstream signals play a key role in wound healing and tissue repair. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] In addition to its plethora of effects on the dynamic interaction among immune and nonimmune cells, it has been found in all cell types involved in fibrotic lesion. [32] [33] [34] [35] We and others have reported multiple mechanisms regarding the activation of TGF-β in IBD. [31] [32] [33] Integrin induces fibrogenesis through integrin binding to the arginine-glycine-aspartate (RGD)-binding domain of N-terminal latency associated peptide (LAP)-TGF-β, resulting in release of active TGF-β from its complex, binding of active TGF-β to its cognate receptors on the cell membrane, and subsequent signal transduction signals. [32] [33] Even though all the isoforms of TGF-β are detectable in fibrotic tissues, including CD, the major factor involved in fibrogenesis is TGF-β1. [23] Moreover, mRNA expression and protein levels of TGF-β1 in strictured colon are significantly upregulated relative to normal colon and normal resection margin from the same patient with CD. Gene transfer of TGF-β1 has also been shown to reproduce experimental colitis in mice. [34] Bidirectional functional crosstalk between TGF-β signals and aberrant expression of microRNAs (miRNAs or miRs) has been reported in a variety of human diseases and animal models, including multiple organ fibrosis. [36] [37] The TGF-β pathway has been documented to regulate many miRNAs, including miR15/16, miR-21, miR-29b, miR-17~92, miR-106-25, miR-155, miR-181b/d, miR-199a, miR-224, and the miR-200 family. [36] MicroRNA biogenesis and function in physiologcial and pathological conditions miRNAs are small non-coding (18-25 oligonucleotides) RNAs found in metazoans and represent a family of distinctive non-coding RNAs. A number of well-written reviews have presented the general biogenesis of miRNA. [38] [39] [40] [41] [42] [43] [44] Therefore, I will provide only a brief introduction here. In general, miRNAs are transcribed into primary miRNA (pri-mRNA) about 100 nucleotides in length in the nucleus by RNA polymerase II. Pri-miRNAs contain characteristic stem-loop or hairpin structures that are cleaved in the Given the critical role of miRNAs in normal and diseased conditions, it is not surprising that miRNAs have multifaceted functions in the pathogenesis of IBD. Unique miRNA expression profiles in tissue samples and peripheral blood have been reported for patients with UC and CD, allowing for the differentiation of IBD diagnosis. [49] Epigenetic regulation of miRNA expression and a critical role of miRNAs in the development and differentiation of immune responses have been uncovered by studies on Th17 signaling, autophagy, and related transcription factors, such as nuclear factor kappa B (NF-κb) and signal transducer and activator of transcription 3 (STAT3). [40, 50] During intestinal barrier dysfunction, the expression of miR-21 is increased, impairing tight junction integrity and increasing barrier permeability through targeting the Rho GTPase RhoB. [51] The study of the role of miRNAs in IBD has received much attention in the field, but the state of research is still in its infancy. Even though there has been much progress in anti-inflammatory treatments of IBD in clinical trials and practice, the frequency of stricture complication postsurgery and after immunotherapy is still high; and no cure that targets fibrosis is currently available. [7] [8] [9] [10] One reason for the lack of a curative treatment is because the mechanism of intestinal fibrosis and the role of miRNAs in this process remain poorly understood.
Epigenetic regulation of intestinal fibrosis
Our understanding of the biological functions of intracellular miRNAs has increased considerably in the last two decades. A growing body of evidence indicates that miRNAs contribute to several cellular processes related to apoptosis, cell proliferation, cell cycle regulation, differentiation, autophagy, unfolded protein response, and the innate and adaptive immune systems. [45] [46] [47] However, the role of miRNAs in the development of intestinal fibrosis in IBD remains largely unknown. The rapidly developing field of epigenetics has demonstrated the great potential for elucidating pathological mechanisms of abnormal gene expression due to the changes of the structure and function of chromatin caused by environmental factors. Epigenetic mechanisms effect gene expression and cellular function through three distinct and interconnected mechanisms: 1) chromatin structure modulation, 2) DNA methylation, and 3) RNA interference by noncoding RNAs. [45] [46] [47] There is growing evidence showing that intestinal fibrosis is modulated by epigenetic mechanisms. Histone deacetylase inhibitors (HDACi) were shown to reduce the mRNA and protein levels of collagen I and the resultant fibrosis in several animal models of fibrosis. [45] [46] [47] HDACs are also involved in EMT and fibroblast activation and differentiation, but the underpinning mechanisms remain unknown. Sadler et al. showed that epigenetic/chromatin changes with histone modification and induction of the collagen 1A2 gene are required for and are important regulators of intestinal EMT. [52] About 10% of miRNA expression is intricately controlled by DNA methylation through DNMTs, which are responsible for both CpG and non-CpG methylation. [40] In an IBD study, Kalla et al. identified among the 65 differentially methylated CpG sites with epigenome-wide significance a correlation between the hypomethylated miR-21 locus and expression of miR-21 expression in leucocytes and affected mucosa. [40] Taken together, these findings suggest that intestinal fibrosis can be modulated at the epigenetic level in IBD.
Functional studies on the role of mirnas in fibrosis of IBD
Although the link between many miRNAs and multiple organ fibrosis, including lung, kidney, heart, liver, and systemic sclerosis, has been studied, there are few studies available that investigate the association with intestinal fibrosis. [38] [39] [40] [41] Here, I summarize the miRNAs associated with intestinal fibrosis (Table 2) . These miRNAs can be divided into "profibrotic" and "antifibrotic" categories, based on their role related to intestinal fibrosis. Profibrotic miRNAs are miRNA-21, miR-192, miR-199, and miR-19, and antifibrotic miRNAs are miR-29b and the miR-200 family. Due to shared pathways in organ fibrosis, miRNAs that have a potential role in intestinal fibrosis are worthy of investigation including miR192, miR-143/145, miR-210, miR-155, miR-199a, miR-19.
miR-21
miR-21 is probably the most widely studied miRNA in IBD, demonstrating consistent and reproducible functional findings in animal models. These data demonstrate that mir-21 may be a potential therapeutic target for fibrosis in multiple organs and other diseases, such as cancer. [42, 44, 51, [53] [54] [55] [56] The role of miR-21 in organ fibrosis is based on accumulating evidence on pulmonary, cardiac, and renal fibrotic disorders. [42, 44, 51, [53] [54] [55] [56] Upregulation of miR-21 expression was observed in affected human tissues as well as in mouse models of fibrosis in different organs. [42, 44, 51, [53] [54] [55] [56] Inhibition of miR-21, either by a miR-21 antagomir or antisense oligonucleotides, reduced and even prevented the progression of experimental organ fibrosis in different mouse models. [44, 53, 55] The precise mechanisms of how profibrotic miR-21 contributed to multiple organ fibrosis may be related to several putative pathways and targets. Since TGF-β has been shown to induce miR-21 expression in cultured cells, including human intestinal myofibroblasts, the TGF-β/Smad canonical pathway is one of the most studied mechanisms of miR-21 function in the development of fibrosis. [53] MiR-21 repressed Smad7 expression while increased Smad3 upregulation through binding to the Smad binding element (SBE) located in the promoter region of Smad3. [53] In carcinoma-associated fibroblasts (CAFs), miR-21 bound to the 3′-UTR of Smad7 and inhibited its translation, but it did not cause its degradation. [54] MiR-21 also enhanced fibrosis through other noncanonical pathways, such as activation of extracellular signal regulated kinase (ERK) and phosphatidylinositol 3 kinase (PI3K)/ AKT signaling by degradation of sprouty (Spry) and phosphatase and tensin homology (PTEN), respectively. [42] Regarding IBD, miR-21 has been shown to play a role in inflammation and tissue injury. miR-21 impairs the tight junction integrity and increases barrier permeability through targeting the Rho GTPase RhoB. [51] Global deletion of miR-21 in mice is protected in dextran sodium sulfate (DSS)-induced colitis but exacerbated in intestinal inflammation in both the 2,4,6-trinitrobenzene sulfonic acid (TNBS) and T cell transfer colitis models. [44] Interestingly, another target of miR-21, proinflammatory programmed cell death 4 (PDCD4), was reported in macrophages, suggesting that there are unexpected anti-inflammatory properties of miR-21 in different cell types. [56] The differential effects of miR-21 in different conditions may reflect diversified pathogenic pathways implicated in each model of colitis, distinctive roles of specific cell types, and preferred targets of miR-21 in specific cell types. [44] miR-29 miR-29 has three mature members, miR-29a, miR-29b, and miR29c that are encoded by two distinct genomic loci. [43] In multiple organs, miR-29 expression was enriched in mesenchyme-derived cells. [43] The promoter regions of miR-29 genes serve as multiple binding sites for several transcription factors, including NF-κB and Smad3. [43] Moreover, growth factors or cytokines, such as TGF-β, TNF-α, and interleukin (IL)-4, suppress miR-29 expres- [43, [61] [62] Regarding the potential profibrotic role of miR-21 and antifibrotic role of miR-29b in fibrosis, our group studied the function of miR-21 and miR-29b in intestinal fibrosis of CD. Differential expression pattern of miR-21 and miR-29b were identified in subepithelial myofibroblasts from fibrostenotic phenotype of CD compared to normal resection margin within the same patient as well as other phenotypes. Smad3 gene was identified as the posttranscriptional target for both miRNAs. [66] In their study, exogenous overexpression of both miR-141 and miR-200a in rat proximal tubular epithelial cells (NRK52E) reduced TGF-β2 and Smad3 activity and ECM protein levels and prevented EMT. The decreased expression of miR-200 family may be partially related to DNA hypermethylation at the promoter regions of these miRNAs in fibrotic disorders. [66] 
miR-192
Wu et al. found a significant reduction of miR-192 expression in active UC tissues and an inverse correlation between miR-192 expression and macrophage inflammatory peptide-2α (MIP-2α), which is produced by colonic epithelial cells and macrophages and highly expressed in active UC tissues relative to healthy control tissues. [49] However, overexpression of miR-192 in colonic epithelial HCT116 cells suppressed NOD2 expression, muramyl dipeptide-mediated NF-κB activation, and gene expressions of IL-8 and chemokine (C-X-C motif) ligand 3, CXCL3. [67] A single nucleotide polymorphism (SNP) (rs3135500) located in the NOD2 3′-UTR significantly decreased the effect of miR-192 on NOD2 mRNA level. [67] Interestingly, in glomerular mesangial cells, miR-192 was upregulated by TGF-β through induction of ets-1 expression under diabetic conditions. [68] In the same study, TGF-β treatment or transfection with miR-192 decreased expression of Smad-interacting protein 1 (SIP1), a novel target of miR-192 that is structurally similar to another E-box transcriptional repressor, δEF1, i.e., the transcription factor ZEB1. [68] Further, Arthur et al. reported in tubular epithelial cells that Smad3, but not Smad2, mediated TGF-β1-induced miR-192 expression through binding to the Smad-binding sites in the miR-192 promoter. [69] In addition, miR-192 was shown to be highly expressed in the kidney and liver. [70] Interestingly, in vitro treatment with anti-miR-29b, miR-21, and miR-192 mimics inhibited the effects of Smad7 overexpression on renal fibrosis in tubular epithelial cells, which suggests that these microRNAs act downstream of Smad7 to override Smad7 function. Restoration of renal miR-29b with suppression of miR-192 and miR-21 may be the mechanism for Smad7 gene therapy inhibition of renal fibrosis. [71] Taken together, these findings suggest that caution should be taken before we consider miR-192 as a potential therapeutic target for anti-inflammation due to its unwanted profibrotic effects and tissue specific expression pattern.
miR-143/145
Previously, Qian et al. showed that insulin-like growth factor 1 receptor (IGF-1R) was the direct target of miR-143 and that its expression was inversely correlated with miR-143 expression in human colorectal tumor tissue. [72] Two recently published articles discussed the role of miR-143/145 in the pathogenesis of colon cancer in vitro and in vivo. In mice with constitutional or tissue-restricted deletion of miR-143/145, Chivukula et al. found that excessive secretion of insulin-like growth factor binding protein 5 (IGFBP5) by mesenchymal cells of the intestine, including myofibroblasts, resulted in decreased phosphorylation of epithelial IGF1R, which may contribute to defects in epithelial regeneration due to impaired IGF signaling after epithelial injury. [73] In the azoxymethane (AOM)/DSS-induced mouse model of colitis-associated cancer, Josse et al. identified PI3K/Akt and IGF1 as major signaling pathways affected by downregulation of miR-143/145 and other miRNAs. [74] Moreover, they also found that miR-143 can affect the PI3K/Akt pathway in an IGF-1R independent manner.
miR-210
miR-210 is considered a signature of hypoxia and a master "hypoxamiR", which is a subset of miRNAs induced by hypoxia. [75] HIF-1α was shown to upregulate miR-210 through its binding to the hypoxia responsive element (HRE) located on the proximal promoter of miR-210. [75] Wang et al. identified Hif1a as a novel target of miR-210, suggesting that miR-210 can inhibit HIF-1a expression through a negative feedback loop. Deletion of miR-210 promoted Th17 differentiation under hypoxic conditions. In a T cell transfer model of colitis, miR-210 was demonstrated to be an important regulator of T cell differentiation via reducing Hif1a mRNA levels and the number of cells that produced inflammatory cytokines, thereby limiting intestinal immunopathology. [76] Study of primary mesenchymal cells isolated from patients with idiopathic pulmonary fibrosis (IPF) showed that increased miR-210 expression drove fibroblast proliferation by repressing the c-myc inhibitor (MNT), while knockdown of miR-210 decreased hypoxia-induced IPF fibroblast proliferation and correlated with increased MNT expression. [77] 
miR-155
In an early study, Das et al. showed that TGF-β induced miR-155 in lamina propria T cells (LPT) and that T-cell miR-155 overexpression decreased mRNA levels of IL-2 and inducible T-cell kinase (ITK), a functional target of miR-155. Antagonism of miR-155 restored the levels of both mRNAs in activated cells. [78] In the DSS colitis model in miR-155 knockout mice, the number of Th1/Th17, CD11 b+ , and CD11 c+ cells was decreased, consistent with attenuation of intestinal damage from experimental colitis. [79] In one of two human UC studies, Min et al. found that miR-155 downregulated forkhead box O3a (FOXO3a) and activated the NFκB pathway in active UC tissues. [80] Moreover, the level of miR-155 was increased in intestinal myofibroblasts isolated from patients with active UC relative to those from healthy control and CD patients, through downregulation of suppressor of cytokine signaling-1 (SOCS1). [81] Paraskevi et al. reported that miR-155 was the most highly expressed of the six UC-associated miRNA in blood samples using real-time polymerase chain reaction (PCR). [82] 
miR-199a
Most studies on the role of miR-199a in fibrosis were performed in pulmonary and liver fibrosis. Zhang et al. identified the AKT/miR199a-5p/caveolin 1 pathway as a regulator of innate immunity that is dysregulated in cystic fibrosis macrophages, which contributes to the lung hyper-inflammation response. [83] MiR-199a-5p expression was induced with TGF-β exposure, and ectopic expression of miR-199a-5p was sufficient to promote the pathogenic activation of pulmonary fibroblasts, including proliferation, migration, invasion, and differentiation into myofibroblasts. In addition, miR-199a-5p is also a key effector of TGFβ signaling in lung fibroblasts by regulating caveolin 1, a critical mediator of pulmonary fibrosis. [84] In both studies of carbon tetrachloride (CCL 4 )-induced mouse model of liver fibrosis and human liver tissue biopsies from patients with HCV infection, the expression levels of miR-199a, 199a*, 200a, and 200b were increased. [85] A recent study showed that miR-199a-5p targeted the pleckstrin homology (PH) domain and leucine-rich repeat protein phosphatase 1 (PHLPP1). PHLPP1 is a tumor suppressor that negatively regulates the AKT pathway and may render colon cancer cells insensitive to treatment with the epidermal growth factor receptor inhibitor cetuximab (CTX). [86] 
miR-19
The miR-19 family (miR-19a and miR-19b-1) was identified as the key oncogenic component of the polycistronic miR-17~92 cluster. [87] Exogenous expression of miR-19, including miR-19a and miR-19b-1, in lung cancer cells triggered EMT, as shown by mesenchymal-like morphological conversion, downregulation of epithelial proteins, upregulation of mesenchymal proteins, formation of stress fibers, and reduction of cell adhesion. [88] Transglutaminase-2 (TG2), a critical cross-linking enzyme in ECM and tumor microenvironment was identified as a target for miR-19 by in silico analysis and was confirmed by a functional study. [89] Overexpression of pre-miR-19a in a cell model of metastatic colon cancer and decreased TG2 expression were linked to chromosome-13 amplification events, leading to enhanced invasion. [89] A recent study in CD showed low serum levels of miR-19a-3p and that miR-19b-3p was associated with a stricturing phenotype of CD and could be used as a potential circulating marker for stricturing CD. [90] This low level of miR-19 in serum may be associated with active DNMT-1 expression and methylation of the miR-17~92 promoter, which was identified in human IPF tissue and fibroblasts and mouse fibrotic lung tissue. [91] Cheng et al. found that miR-19b directly recognized the 3′-UTR of SOCS3 and inhibited its expression, leading to increased macrophage-inflammatory protein-3 α (MIP-3α) and suppression of inflammatory response in intestinal epithelial cells. [92] These aforementioned studies shed light on developing therapeutic methods in fibrotic diseases. Spatial and temporal expression of specific miRNAs in the gut play a critical role in orchestrating fundamental cellular processes and maintaining intracellular homeostasis before they are dysregulated in the pathological conditions of fibrosis.
Based on previous findings of different miRNAs in epigenetic regulation of TGF-β and EMT, I hypothesized potential mechanisms of profibrotic and antifibrotic miRNAs in the regulation of TGF-β signals at multiple levels in the development of intestinal fibrosis in IBD. In Fig. 1 , profibrotic miRNAs, such as miR-21, miR-199a, and miR-192, enhance TGF-β signals at different levels by targeting not only the upstream TGF-β receptor, Smad3, or the integral membrane protein, caveolin 1, but also downstream fibrotic gene products and collagens. The fibrotics miR-19 and miR-192 may target EMT/ZEB family members. In contrast, antifibrotic miRNAs may inhibit the same molecules in TGF-β signaling. For example, miR-29b may inhibit multiple targets (mainly ECM-related genes) during TGF-β signaling activation. In summary, the epigenetic dysregulation of profibrotic and antifibrotic miRNAs regulates TGF-β signaling during the development of intestinal fibrosis. Better understanding of the role of different miRNAs and the regulation of aberrant expression of miRNAs may provide us novel insights into the mechanism(s) underlying intestinal fibrosis, potential therapeutic target(s), and a promising diagnostic or evaluation tool before and after treatment for IBD patients, specifically with fibrostenotic CD.
Challenges in microRNA research
Currently, the field of miRNA research is growing dramatically, as shown by the stunning number of miRNA-related publications covering almost all biomedical research topics found in PubMed. The importance of miRNAs in normal physiology and disease is already known. [38] [39] [40] [41] However, in order to understand the role of individual miRNAs in intestinal fibrosis of IBD, we have to consider real challenges that need to be overcome in miRNA research. First, it is difficult to interpret and compare the profile of miRNAs among different groups because there is a lack of standardization of experimental design and data analysis, such as different concepts of control groups and different approaches to normalize miRNA data. Second, it is difficult to evaluate contradictory data related to individual miRNA expression patterns in different organ systems or in samples of different origins (serum vs. tissue biopsies and immune cells vs. mesenchymal cells) due to cell-typespecific and tissue-type-specific expression of miRNA. [40] Third, targeted delivery of miRNAs of interest in vivo using synthetic antisense oligonucleotides or mimics needs to be stable in serum and avoid enzymatic degradation and renal clearance. In addition, miRNA needs to be delivered specifically to the target organ in order to minimize off-target effects, i.e., toxicity in normal tissues and activation of redundant signals because of miRNA networks. The short-term and long-term side effects need to be evaluated as well. [93] In contrast to the use of lentiviral vectors for in vivo delivery, which poses safety concerns, emerging exosomal delivery of extracellular miRNAs packaged in vesicles seems to be much more promising. [94] [95] [96] With the emergence of the Genome wide associated study (GWAS) in the past decade, researchers and physicians better understand the pathogenesis of IBD within a broader genetic background. [97] [98] [99] Most of the genetic variants associated with particular autoimmune diseases are shared between other systemic and specific organ-targeted autoimmune and inflammatory diseases. [98] [99] Key mechanisms defined from 163 IBD susceptible loci for IBD offer us a powerful tool to interconnect individual miRNAs using a bioinformatics-generated miRNA target database.
The development of better therapeutic targets depends on our understanding of intestinal fibrosis in CD. Through collaboration with multiple IBD research centers, novel techniques and systematic biologic approaches, for example, GWAS together with whole exosome sequencing analysis, are elaborated into the current IBD research consortium to generate a huge database composed of patients' lab records and tissue banks that include patients' serum, plasma and surgical or biopsy specimens. Because of these resources, we may identify more specific gene loci as well as corresponding SNPs at related chromosomes based on underlying molecular and cellular mechanisms, thereby allowing for a tailored or individualized therapy regimen depending on the type and stage of CD in each patient.
In Fig. 2, I summarize the strategy used for miRNA design and study in translational biomedical research (Fig. 2) .
Conclusions
Cellular components, such as mesenchymal cells, and core molecular processes, such as TGF-β pathway, are critical in fibrotic events. miRNAs play a key role in the regulation of gene expres- sion at post-transcriptional levels. In this review, I presented the most recent findings on the differential expression of miRNAs in the regulation of diversified signal pathways in human diseases and animal models. Based on these functional studies, miRNAs in IBD could play a critical role in modulation of TGF-β pathway at multiple levels in order to manage dysregulated intestinal homeostasis. I also address the potential challenges in miRNA studies and offer some suggestions to overcome these obstacles.
Future Directions
From a clinical perspective, intestinal fibrosis is not driven solely by chronic inflammation-mediated immunological response to stimulants. Control of inflammation through clinical intervention is not enough to combat complicated intestinal fibrosis. Better understanding of the pathogenesis of intestinal fibrosis in IBD requires integration of signal network information related to 163 risk loci, which were discovered by GWAS. In the near future, the study of cell-type specific and tissue specific expression of miRNAs may better our understanding of the function of miRNAs in the regulation of common fibrotic pathway, such as TGF-β signaling. How we interpret miRNA data obtained from human and animal studies, which are related to IBD loci in GWAS findings, autophagy, and immune response, represents new opportunities for basic research in this field. Current strategies for miRNA research should be standardized across labs. These include strategies for selection of the right controls for patients with different subtypes, interpretation of miRNA data with correct miRNA internal controls, and uniformed protocols to process tissue samples.
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